Synthego Launches High-Value IVT Enzymes for Advanced RNA Therapeutics

REDWOOD CITY, CA, November 4, 2024 –

Synthego has expanded its solutions portfolio with the introduction of high-performance RNA enzymes, T7 RNA Polymerase and RNase Inhibitor, further enhancing its capabilities to serve the RNA research and therapeutic markets. These newly launched in vitro transcription (IVT) enzymes are specifically designed to address critical challenges in RNA synthesis and manipulation, complementing Synthego’s industry-leading gRNAs.

The T7 RNA Polymerase enables efficient RNA synthesis with high yield and purity, making it ideal for applications such as mRNA therapeutics, gene editing platforms, and synthetic biology workflows. Complementing this, the RNase Inhibitor safeguards RNA integrity by protecting against degradation during complex workflows, ensuring reliability and consistency in sensitive experiments. Together, these enzymes empower researchers with tools designed to streamline processes and optimize results, from discovery through clinical development.

Together, these enzymes integrate seamlessly with Synthego's best-in-class gRNA solutions, providing researchers with a complete and robust toolkit for applications ranging from RNA therapeutic development to gene editing and prime editing. With these tools, researchers can confidently accelerate the progression of RNA-centric projects, from initial discoveries to advanced therapeutic development. For detailed specifications, visit our T7 RNA Polymerase and RNase Inhibitor product pages.